4320 Forest Park Avenue
The company was founded as Vasculox, Inc., by scientific founders including William A. Frazier, PhD, professor of Biochemistry, Molecular Biophysics, Cell Biology, and Biomedical Engineering at Washington University School of Medicine. Dr. Frazier was instrumental in the discovery that CD47 is a receptor for thrombospondin-1 and he has been a leader in the field of CD47-mediated signaling pathways for many years. Tioma maintains its research laboratories in St. Louis and a corporate office in the San Francisco Bay Area. The company has generated a portfolio of anti-CD47 antibodies that have the potential to surmount multiple checkpoints by which cancer evades the immune system. These antibodies are protected by a strong, multilayered intellectual property estate that includes composition-of-matter and uses of humanized anti-CD47 antibodies. For more information, please visit www.tiomatherapeutics.com.
Founder: William A. Frazier, Ph.D. and Pamela T. Manning, Ph.D.
CEO: John Donovan
CSO: Robert W. Karr, MD
CBO: James Stutz
Please click here for Tioma Therapeutics job opportunities.